The board of directors of CSPC Pharmaceutical Group Limited announce that the recombinant fully human anti-Klotho monoclonal antibody drug (JMT202) (the ?Product?) developed by the Group, has obtained approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China. The Product is an FGFR1c/Klotho receptor agonist, which regulates glycolipid metabolism by binding to Klotho protein and specifically activating the FGFR1c/Klotho receptor complex, thereby mimicking the action of its natural ligand, FGF21 protein. The Product is potentially useful for the treatment of metabolism-related diseases such as dyslipidemia, non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity.

Furthermore, it has the potential to be used in combination with other targeted drugs (such as GLP-1) that regulate glycolipid metabolism. The indication for this clinical trial approval is to lower triglyceride (TG) levels in patients with hypertriglyceridaemia. Preclinical studies demonstrated that the Product has a good safety profile, long dosing intervals, significant reduction in triglycerides levels, and hypolipidemic effect on the liver, thus providing a promising clinical development value.